Rigel Pharmaceuticals (RIGL) Finished Goods (2018 - 2026)

Rigel Pharmaceuticals' Finished Goods history runs 9 years deep, the most recent figure standing at $4.1 million for Q1 2026.

• On a quarterly basis, Finished Goods rose 9.05% year-over-year to $4.1 million in Q1 2026; TTM through Mar 2026 was $4.1 million, a 9.05% increase from a year earlier, with the FY2025 full-year figure at $4.7 million, down 6.02% from the prior year.
• Finished Goods slipped to $4.1 million in Q1 2026 per RIGL's latest filing, from $4.7 million in the prior quarter.
• Across five years, Finished Goods topped out at $5.8 million in Q3 2024 and bottomed at $1.1 million in Q2 2022.
• The 5-year median for Finished Goods is $2.0 million (2022), against an average of $2.8 million.
• Across the five-year window, Finished Goods soared 232.49% in 2024 and slumped 69.37% in 2025, its largest moves.
• Year by year, Finished Goods stood at $1.9 million in 2022, then dropped by 20.8% to $1.5 million in 2023, then surged by 232.49% to $5.0 million in 2024, then slipped by 6.02% to $4.7 million in 2025, then dropped by 13.05% to $4.1 million in 2026.
• Per Business Quant, the three latest RIGL Finished Goods figures stand at $4.1 million (Q1 2026), $4.7 million (Q4 2025), and $1.8 million (Q3 2025).